Publications by authors named "Kelly A Berry"
In 2018, the United States Food and Drug Administration (FDA) approved Aimovig (erenumab) for the prevention of migraine. Erenumab is the first FDA approved antibody therapeutic against a G-protein-coupled receptor, the canonical receptor of calcitonin gene related peptide (CGRP-R). A novel, epitope-focused antigen was created to reconstruct the extracellular domains of the CGRP-R in a stable conformation.
View Article and Find Full Text PDFArticle Synopsis
- The study presents a rapid and flexible technique called NanOBlast for screening antibodies from single B lymphocyte cells, crucial for developing therapeutic antibodies.
- This method involves isolating antibody-secreting cells from mice, screening their secreted antibodies using advanced microfluidic technology, and identifying high-affinity anti-idiotypic mAbs.
- The entire antibody discovery process can be completed in under 60 days, significantly speeding up drug development and enabling precise assays for measuring therapeutic IgG levels in patient serum.
A key step in the therapeutic antibody drug discovery process is early identification of diverse candidate molecules. Information comparing antibody binding epitopes can be used to classify antibodies within a large panel, guiding rational lead molecule selection. We describe a novel epitope binning method utilizing high-throughput flow cytometry (HTFC) that leverages cellular barcoding or spectrally distinct beads to multiplex samples to characterize antibodies raised against cell membrane receptor or soluble protein targets.
View Article and Find Full Text PDF